The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
Open accessAbstract
BACKGROUND: The discovery that heterozygous missense mutations in the gene encoding triggering receptor expressed on myeloid cells 2 (TREM2) are risk factors for Alzheimer's disease (AD), with only the apolipoprotein E (APOE) ε4 gene allele conferring a higher risk, has led to increased interest in immune biology in the brain. TREM2 is expressed on microglia, the resident immune cells of the brain and has been linked to phagocytotic clearance of amyloid β (Aβ) plaques. Soluble TREM2 (sTREM2) has previously been measured in cerebrospinal fluid (CSF) by ELISA but in our hands commercial kits have proved unreliable, suggesting that other methods may be required. We developed a mass spectrometry method using selected reaction monitoring for the presence of a TREM2 peptide, which can be used to quantify levels of sTREM2 in CSF. FINDINGS: We examined CSF samples from memory clinics in Sweden and the UK. For all samples the following were available: clinical diagnosis, age, sex, and measurements of the CSF AD biomarkers Aβ42, T-tau and P-tau181. AD patients (n = 37) all met biomarker (IWG2) criteria for AD. Control individuals (n = 22) were cognitively normal without evidence for AD in CSF. We found significantly higher sTREM2 concentration in AD compared to control CSF. There were significant correlations between CSF sTREM2 and T-tau as well as P-tau181. CSF sTREM2 increase in AD was replicated in a second, independent cohort consisting of 24 AD patients and 16 healthy volunteers. CONCLUSION: CSF concentrations of sTREM2 are higher in AD than in controls, and correlate with markers of neurodegeneration. CSF sTREM2 may be used to quantify glial activation in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This could be representative of changes in TREM2 expression or shedding, both of which are altered during ageing and disease [55], thereby reducing TREM2-mediated signalling and subsequent conversion of microglia to DAM [56].”
From TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation (2021) · cites this paper as [55]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0027 · Cited by 3,889
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Self-citationVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Qualitative Assessment of Verbal Fluency Performance in Frontotemporal Dementia
van den Berg, E., Jiskoot, L. C., Grosveld, M. J. H., Swieten, J. C. V., & Papma, J. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477538 · Cited by 2,065
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationTakahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896
Research works printed but not linked: 1
- Benitez BA, Cruchaga C. TREM2 and neurodegenerative disease. N Engl J Med. 2013;369(16):1567–8.
Cited by
Sorted by citations
Items 101–200 of 303
CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
Henjum, K., Quist‐Paulsen, E., Zetterberg, H., Blennow, K., Nilsson, L. N. G., & Watne, L. O. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1331-1 · Cited by 56
Self-citationPocock, J., Vasilopoulou, F., Svensson, E., & Cosker, K. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110020 · Cited by 54
Role of TREM2 in Alzheimer’s Disease: A Long Road Ahead
Kulkarni, B., Kumar, D., Martins, N. A., & Sellamuthu, S. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02477-9 · Cited by 53
Clinical significance of fluid biomarkers in Alzheimer’s Disease
Lewczuk, P., Łukaszewicz‐Zając, M., Mroczko, P., & Kornhuber, J. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00107-0 · Cited by 56
Blood-Based Biomarkers of Neuroinflammation in Alzheimer’s Disease: A Central Role for Periphery?
Angiulli, F., Conti, E., Zoia, C., Re, F. D., Appollonio, I. M., Ferrarese, C., & Tremolizzo, L. (2021) · Diagnostics · doi:10.3390/diagnostics11091525 · Cited by 55
Gispert, J. D., Monté, G. C., Suárez‐Calvet, M., Falcón, C., Tucholka, A., Rojas, S., Rami, L., Sánchez‐Valle, R., Lladó, A., Kleinberger, G., et al. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.12.002 · Cited by 53
Obrocki, P., Khatun, A., Ness, D., Senkevich, K. A., Hanrieder, J., Capraro, F., Mattsson, N., Andréasson, U., Portelius, E., Ashton, N. J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00586-6 · Cited by 51
Self-citationThe role of TREM2 in Alzheimer’s disease: from the perspective of Tau
Huang, W., Huang, J., Huang, N., & Luo, Y. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1280257 · Cited by 49
Timsina, J., Ali, M., Do, A. N., Wang, L., Western, D., Sung, Y. J., & Cruchaga, C. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106373 · Cited by 48
Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease
Perez, S. E., Nadeem, M., He, B., Miguel, J. C., Malek‐Ahmadi, M. H., Chen, K., & Mufson, E. J. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.02.012 · Cited by 51
Soluble TREM2 and Inflammatory Proteins in Alzheimer’s Disease Cerebrospinal Fluid
Rauchmann, B., Sadlon, A., Perneczky, R., & Initiative, A. D. N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191120 · Cited by 50
Knapskog, A., Henjum, K., Idland, A., Eldholm, R. S., Persson, K., Saltvedt, I. T., Watne, L. O., Engedal, K., & Nilsson, L. N. G. (2020) · Scientific Reports · doi:10.1038/s41598-020-72878-8 · Cited by 53
Review: Fluid biomarkers for frontotemporal dementias
Zetterberg, H., van Swieten, J. C., Boxer, A. L., & Rohrer, J. D. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12530 · Cited by 48
Self-citationThe Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
Yin, X., Qiu, Y., Zhao, C., Zhou, Z., Bao, J., & Qian, W. (2021) · Medical Science Monitor · doi:10.12659/msm.933084 · Cited by 48
Deming, Y. K., Li, Z., Benítez, B. A., & Cruchaga, C. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1486823 · Cited by 51
The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer’s disease
Park, S., Lee, E.-H., Kim, H., Jo, S., Lee, S., Seo, S. W., Park, H.-H., Koh, S., & Lee, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-92101-6 · Cited by 53
Woollacott, I., Nicholas, J. M., Heller, C., Foiani, M. S., Moore, K. M., Russell, L. L., Paterson, R. W., Keshavan, A., Schott, J. M., Warren, J. D., et al. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000506282 · Cited by 49
Self-citationTREM2 expression and amyloid‐beta phagocytosis in Alzheimer's disease
La Rosa, F., Agostini, S., Piancone, F., Marventano, I., Hernis, A., Fenoglio, C., Galimberti, D., Scarpini, E., Saresella, M., & Clerici, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108626 · Cited by 50
Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers
Ashton, N. J., Suárez‐Calvet, M., Heslegrave, A., Hye, A., Razquín, C., Pástor, P., Sánchez‐Valle, R., Molinuevo, J. L., Visser, P. J., Blennow, K., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0545-5 · Cited by 45
Self-citationSchmitz, T. W., Soreq, H., Poirier, J., & Spreng, R. N. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1184-19.2019 · Cited by 47
Plasma soluble TREM2 is associated with white matter lesions independent of amyloid and tau
Tsai, H.-H. C., Chen, Y., Yen, R., Lo, Y.-L., Yang, K., Jeng, J., Tsai, L., & Chang, C.-F. (2021) · Brain · doi:10.1093/brain/awab332 · Cited by 47
Does soluble TREM2 protect against Alzheimer's disease?
Brown, G. C., & St George-Hyslop, P. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.834697 · Cited by 39
TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation
Moutinho, M., Coronel, I., Tsai, A. P., Di Prisco, G. V., Pennington, T., Atwood, B. K., Puntambekar, S. S., Smith, D. C., Martinez, P., Han, S., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01160-z · Cited by 42
TDP-43 Proteinopathy Specific Biomarker Development
Cordts, I., Wachinger, A., Scialò, C., Lingor, P., Polymenidou, M., Buratti, E., & Feneberg, E. (2023) · Cells · doi:10.3390/cells12040597 · Cited by 50
Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
Alawode, D. O. T., Fox, N. C., Zetterberg, H., & Heslegrave, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.837390 · Cited by 41
Self-citationGao, C., Shen, X., Tan, Y., & Chen, S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02580-1 · Cited by 48
ApoE4-Mediated Blood Brain Barrier Damage in Alzheimer's Disease: Progress and Prospects
Zhou, X., Shi, Q., Zhang, X., Gu, L., Li, J., Ju, Y., Hu, M., Zhao, X., & Li, Q. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110670 · Cited by 40
Winfree, R. L., Seto, M., Dumitrescu, L. C., Menon, V., Jager, P. L. D., Wang, Y., Schneider, J. A., Bennett, D. A., Jefferson, A. L., & Hohman, T. J. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02564-2 · Cited by 39
Roles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer's Disease
Lin, M., Yu, J., Zhang, W., Lao, F., & Huang, H. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.164 · Cited by 46
Hou, X., Bi, Y., Tan, M., Xu, W., Li, J., Shen, X., Dou, K., Tan, C., Tan, L., & Yu, J. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.05.008 · Cited by 40
The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer’s Disease
Zhong, L., & Chen, X. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00328 · Cited by 40
Wagemann, O., Liu, H., Wang, G., Shi, X., Bittner, T., Scelsi, M. A., Farlow, M. R., Clifford, D. B., Supnet, C. B., Santacruz, A. M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.0991 · Cited by 40
Sekiya, M., Wang, M., Fujisaki, N., Sakakibara, Y., Quan, X., Ehrlich, M. E., De Jager, P. L., Bennett, D. A., Schadt, E. E., Gandy, S., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0530-9 · Cited by 38
More than just risk for Alzheimer’s disease: APOE ε4's impact on the aging brain
Palmer, J. M., Huentelman, M. J., & Ryan, L. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.06.003 · Cited by 39
CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia
Heywood, W., Hällqvist, J., Heslegrave, A., Zetterberg, H., Fenoglio, C., Scarpini, E. A., Rohrer, J. D., Galimberti, D., & Mills, K. A. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.019 · Cited by 37
Self-citationBiomarkers: Our Path Towards a Cure for Alzheimer Disease
Tarawneh, R. M. (2020) · Biomarker Insights · doi:10.1177/1177271920976367 · Cited by 42
Microglia in Alzheimer's Disease: A Role for Ion Channels
Thei, L., Imm, J. L., Kaisis, E., Dallas, M. L., & Kerrigan, T. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00676 · Cited by 37
Role of Rab GTPases in Alzheimer’s Disease
Zhang, X., Huang, T. Y., Yancey, J., Luo, H., & Zhang, Y. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00387 · Cited by 37
Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer’s disease: a longitudinal study
Nabizadeh, F., Seyedmirzaei, H., & Karami, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-66211-w · Cited by 36
Falcón, C., Monté, G. C., Grau‐Rivera, O., Suárez‐Calvet, M., Sánchez‐Valle, R., Rami, L., Bosch, B., Haass, C., Gispert, J. D., & Molinuevo, J. L. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101801 · Cited by 36
Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease
Byrne, L. M., Rodrigues, F. B., Johnson, E. B., Vita, E. D., Blennow, K., Scahill, R. I., Zetterberg, H., Heslegrave, A., & Wild, E. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-21788-x · Cited by 31
Self-citationEdwin, T. H., Henjum, K., Nilsson, L. N. G., Watne, L. O., Persson, K., Eldholm, R. S., Saltvedt, I. T., Halaas, N. B., Selbæk, G., Engedal, K., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12128 · Cited by 35
The sTREM2 Concentrations in the Blood: A Marker of Neurodegeneration?
Ferri, E., Rossi, P. D., Geraci, A., Ciccone, S., Cesari, M., & Arosio, B. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.627931 · Cited by 36
TREM2 expression in the brain and biological fluids in prion diseases
Diaz-Lucena, D., Kruse, N., Thüne, K., Schmitz, M., Villar-Piqué, A., da Cunha, J. E. G., Hermann, P., López-Pérez, Ó., Andrés-Benito, P., Ladogana, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02296-1 · Cited by 32
Self-citationThe role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2
Shirotani, K., Hatta, D., Wakita, N., Watanabe, K., & Iwata, N. (2022) · The Journal of Biochemistry · doi:10.1093/jb/mvac073 · Cited by 31
Roles of TREM2 in Alzheimer’s disease
Qi, X., Zhu, K., Ke, W., Wang, J., Mao, S., & Chen, G. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00515-3 · Cited by 38
Duggan, S. P., Garry, C., Behan, F. M., Phipps, S., Kudo, H., Kirca, M., Zaheer, A., McGarrigle, S. A., Reynolds, J. V., Goldin, R. D., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.01.012 · Cited by 32
Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer’s Disease
Meier, S. R., Sehlin, D., Hultqvist, G., & Syvänen, S. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01591-3 · Cited by 32
CSF sTREM2 in neurological diseases: a two-sample Mendelian randomization study
Dong, M.-H., Zhou, L.-Q., Tang, Y., Chen, M., Xiao, J., Shang, K., Deng, G., Qin, C., & Tian, D.-S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02443-9 · Cited by 31
Biological correlates of elevated soluble TREM2 in cerebrospinal fluid
Winfree, R. L., Dumitrescu, L. C., Blennow, K., Zetterberg, H., Gifford, K. A., Pechman, K. R., Jefferson, A. L., & Hohman, T. J. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.06.013 · Cited by 31
Self-citationEarly microglial and astrocyte reactivity in preclinical Alzheimer's disease
Fernández‐Matarrubia, M., Barrero, A. V., Renuncio‐García, M., Aguilella, M., Lage, C., López‐García, S., Ocejo-Vinyals, J. G., Martínez‐Dubarbie, F., Molfetta, G. D., Pozueta‐Cantudo, A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70502 · Cited by 37
Self-citationSalvadó, G., Milà‐Alomà, M., Shekari, M., Minguillón, C., Fauria, K., Niñerola‐Baizán, A., Perissinotti, A., Kollmorgen, G., Buckley, C. J., Farrar, G., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12245 · Cited by 30
Self-citationTREM2 in Alzheimer's disease: Structure, function, therapeutic prospects, and activation challenges
Zgórzyńska, E. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103917 · Cited by 29
TREMs in Alzheimer's disease: Genetic and clinical investigations
Cheng, J. R., Guo, X., Zhang, T., Zhong, L., Bu, G., & Chen, X. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.10.022 · Cited by 29
The blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases
Barro, C., & Zetterberg, H. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109281 · Cited by 30
Self-citationIncreased CSF Soluble TREM2 Concentration in Patients With Neurosyphilis
Li, W., Chang, H., Wu, W., Xu, D., Jiang, M., Gao, J., Huang, Y., Xu, Y., Yin, L., & Zhang, X. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00062 · Cited by 49
Xu, M., Zhou, M., Li, S., Zhen, X., & Yang, S. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24805 · Cited by 27
Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer’s Disease
Liu, C., & Yu, J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00297 · Cited by 27
Peng, G., Qiu, J., Liu, H., Zhou, M., Huang, S., Guo, W., Lin, Y., Chen, X. '., Li, Z., Li, G., et al. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01424-7 · Cited by 30
Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer’s disease: an update
Portelius, E., Brinkmalm, G., Pannee, J., Zetterberg, H., Blennow, K., Dahlén, R., Brinkmalm, A., & Gobom, J. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1384697 · Cited by 26
Self-citationWeber, G. E., Koenig, K. A., Khrestian, M., Shao, Y. Y., Tuason, E. D., Gramm, M., Lal, D., Leverenz, J. B., & Bekris, L. M. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901166 · Cited by 27
Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine Approach
Prete, E. D., Beatino, M. F., Campese, N., Giampietri, L., Siciliano, G., Ceravolo, R., & Baldacci, F. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040221 · Cited by 29
Intracellular trafficking of TREM2 is regulated by presenilin 1
Zhao, Y., Li, X., Huang, T. Y., Jiang, L.-L., Tan, Z., Zhang, M., Cheng, I. H.-J., Wang, X., Bu, G., Zhang, Y., et al. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.200 · Cited by 26
Implication of tau propagation on neurodegeneration in Alzheimer’s disease
Lamontagne-Kam, D., Ulfat, A. K., Hervé, V., Vu, T.-M., & Brouillette, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1219299 · Cited by 28
Lu, Y., Zhao, Y., Zhang, Q., Fang, C., Bao, A., Dong, W., Peng, Y., Peng, H. Y., Ju, Z., He, J., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02440-y · Cited by 24
Wang, R., Zhan, Y., Zhu, W., Yang, Q., & Pei, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1407980 · Cited by 25
Lin, C., Kong, Y., Chen, Q., Zeng, J., Pan, X., & Miao, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1420731 · Cited by 24
TREM2 in Neurodegenerative Disorders: Mutation Spectrum, Pathophysiology, and Therapeutic Targeting
Yang, H.-W., Kim, D., Yang, Y., Bagyinszky, E., & An, S. S. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157057 · Cited by 26
Fluid Biomarkers for Chronic Traumatic Encephalopathy
Shahim, P., Gill, J., Blennow, K., & Zetterberg, H. (2020) · Seminars in Neurology · doi:10.1055/s-0040-1715095 · Cited by 24
Self-citationWittrahm, R., Takalo, M., Kuulasmaa, T., Mäkinen, P. M., Mäkinen, P., Končarević, S., Fartzdinov, V., Selzer, S., Kokkola, T., Antikainen, L., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106140 · Cited by 22
Varnum, M. M., Clayton, K. A., Yoshii-Kitahara, A., Yonemoto, G., Koro, L., Ikezu, S., & Ikezu, T. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.759159 · Cited by 22
Yin, Z., Cheng, X., Wang, G., Chen, J., Jin, Y., Tu, Q., & Xiang, J. (2020) · Microchimica Acta · doi:10.1007/s00604-020-04507-0 · Cited by 22
Khan, M. I., Khan, M. Z., Shin, J. H., Shin, T. S., Lee, Y. B., Kim, M. Y., & Kim, J. D. (2022) · Molecules · doi:10.3390/molecules27072079 · Cited by 24
Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer’s Disease
Xie, J., Wang, H., Lin, T., & Bi, B. (2017) · BioMed Research International · doi:10.1155/2017/2986460 · Cited by 22
Roles of Siglecs in neurodegenerative diseases
Siew, J. J., Chern, Y., Khoo, K., & Angata, T. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101141 · Cited by 20
Beckmann, N., Neuhaus, A., Zurbruegg, S., Volkmer, P., Patiño, C., Joller, S., Feuerbach, D., Doelemeyer, A., Schweizer, T., Rudin, S., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02671-z · Cited by 24
Španić, E., Leko, M. B., Horvat, L. L., Brgić, K., Vogrinc, Ž., Boban, M., Klepac, N., Borovečki, F., & Šimić, G. (2023) · Neurology International · doi:10.3390/neurolint15030053 · Cited by 21
Brinkmalm, A., Portelius, E., Brinkmalm, G., Pannee, J., Dahlén, R., Gobom, J., Blennow, K., & Zetterberg, H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14594 · Cited by 23
Self-citationChronic traumatic encephalopathy: fluid biomarkers
Zetterberg, H., & Blennow, K. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63954-7.00030-6 · Cited by 23
Self-citationPillai, J. A., Khrestian, M., Bena, J., Leverenz, J. B., & Bekris, L. M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.676744 · Cited by 21
CSF sTREM2 and Tau Work Together in Predicting Increased Temporal Lobe Atrophy in Older Adults
Halaas, N. B., Henjum, K., Blennow, K., Dakhil, S., Idland, A., Nilsson, L. N. G., Sederevičius, D., Dídac Vidal-piñeiro, A., Walhovd, K. B., Wyller, T. B., et al. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz240 · Cited by 20
Self-citationEvidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression
Pomara, N., Bruno, D., Plaska, C. R., Pillai, A., Ramos‐Cejudo, J., Osorio, R. S., Imbimbo, B. P., Heslegrave, A., Zetterberg, H., & Blennow, K. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.012 · Cited by 20
Self-citationTREM2 in Neurodegenerative Diseases: Mechanisms and Therapeutic Potential
Li, L., Zheng, X., Ma, H., Zhu, M., Li, X., Sun, X., & Feng, X. (2025) · Cells · doi:10.3390/cells14171387 · Cited by 22
CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia
van der Ende, E. L., Morenas‐Rodríguez, E., McMillan, C. T., Grossman, M., Irwin, D. J., Sánchez‐Valle, R., Graff, C., Vandenberghe, R. R., Pijnenburg, Y. A. L., Laforce, R. J., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.02.024 · Cited by 19
TREM2 in MASH: integrating lipid metabolism and immune response
Shi, S., Zhou, Y. Y., Zhang, H., & Zhang, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604837 · Cited by 21
Microglia Biomarkers in Alzheimer’s Disease
Zhang, P., Hu, H., Tan, L., & Yu, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02348-3 · Cited by 19
Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry
Gobom, J., Brinkmalm, A., Brinkmalm, G., Blennow, K., & Zetterberg, H. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100721 · Cited by 20
Self-citationThe Role of TREML2 in Alzheimer’s Disease
Wang, S., Gong, P., Yan, E., Zhang, Y., & Jiang, T. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200406 · Cited by 18
Advances in Genetic and Molecular Understanding of Alzheimer’s Disease
Ibáñez, L., Cruchaga, C., & Fernández, M. V. (2021) · Genes · doi:10.3390/genes12081247 · Cited by 20
As48, a first-in-class dual-function TREM2 modulator: Receptor activation and shedding inhibition
Cho, S., Gaamouch, F. E., Upadhyay, S., Nada, H., Kuncewicz, K., & Gabr, M. T. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118862 · Cited by 15
Gussago, C., Casati, M., Ferri, E., & Arosio, B. (2019) · The Journal of Frailty & Aging · doi:10.14283/jfa.2018.43 · Cited by 18
Li, T., Initiative, A. D. N., Lyu, D., & Liu, F. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220598 · Cited by 17
Qin, Z., Gu, M., Zhou, J., Zhang, W., Zhao, N., Lü, Y., & Yu, W. (2020) · Synapse · doi:10.1002/syn.22161 · Cited by 19
Shen, Y., Li, X., & Yao, J. (2021) · Gerontology · doi:10.1159/000517511 · Cited by 17
TREM2 signaling in Parkinson’s disease: Regulation of microglial function and α-synuclein pathology
Yin, S., Chi, X., Wan, F. J., Li, Y., Zhou, Q., Kou, L., Sun, Y., Wu, J., Zou, W., Wang, Y., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113446 · Cited by 17
Role of triggering receptor expressed on myeloid cells 2 (TREM2) in neurodegenerative dementias
Shafi, S., Singh, A., Ibrahim, A. M., Alhajri, N., Izneid, T. A., & Pottoo, F. H. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15215 · Cited by 15
Peripheral TREM2 mRNA levels in early and late-onset Alzheimer disease’s patients
Güven, G., Bılgıç, B., Samancı, B., Gurvit, H. I., Hanağası, H. A., Dönmez, Ç., Aslan, R., Lohmann, E., & Erginel‐Ünaltuna, N. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05661-7 · Cited by 15
Wang, K., Cao, X., Li, Z., Liu, S., Zhou, Y., Guo, L., & Li, P. (2022) · BMC Anesthesiology · doi:10.1186/s12871-022-01955-4 · Cited by 16
Functional BRI2-TREM2 interactions in microglia: implications for Alzheimer’s and related dementias
Yin, T., Yesiltepe, M., & D’Adamio, L. (2024) · EMBO Reports · doi:10.1038/s44319-024-00077-x · Cited by 15
Metadata
- Authors
- Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., Mills, K., & Zetterberg, H.
- Affiliations
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
- University of Gothenburg (SE)
- Skaraborg Hospital (SE)
- Corresponding author
- Heslegrave, Amanda
- ORCID
- Venue
- Molecular Neurodegeneration
- Published
- 2016-01-12
- Volume
- 11
- Issue
- 1
- Pages
- 3-3
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC4709982
- OpenAlex
- W2234866329
- Cited by
- 303
- References
- 40
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 43 · 2023: 24 · 2022: 31 · 2021: 39 · 2020: 34 · 2019: 22 · 2018: 39 · 2017: 24 · 2016: 9
- FWCI
- 17.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Wolfson Foundation
- Alzheimer’s Research UK
- Svenska Forskningsrådet Formas
- Biomedical Research Council (GOSH)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- soluble TREM2, Alzheimer's disease, cerebrospinal fluid biomarkers, microglia, neuroinflammation, tau phosphorylation, phosphorylated tau 181, total tau, amyloid-beta, glial activation, multiple reaction monitoring, mass spectrometry quantification
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Receptors, Immunologic, Risk Factors, Biomarkers, Amyloid beta-Peptides, tau Proteins, Apolipoprotein E4, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review